Similar articles

• Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy.

  Aguiar-Bujanda D, Dueñas-Comino A, Cabello C, Bastida J, Rivero-Vera JC, Limeres-González MA. Aguiar-Bujanda D, et al. Eur J Dermatol. 2017 Dec 1;27(6):671-673. doi: 10.1684/ejd.2017.3149. Eur J Dermatol. 2017. PMID: 29165301 No abstract available.
• Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression.

  Saintes C, Saint-Jean M, Renaut JJ, Dréno B, Quéreux G. Saintes C, et al. Br J Dermatol. 2015 Mar;172(3):819-21. doi: 10.1111/bjd.13337. Epub 2015 Jan 18. Br J Dermatol. 2015. PMID: 25113163 No abstract available.
• Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients.

  Papadavid E, Kapniari E, Marinos L, Nikolaou V, Oikonomidi A, Georgakopoulos J, Stratigos A, Kouloulias V, Pappa V. Papadavid E, et al. J Eur Acad Dermatol Venereol. 2019 May;33(5):e223-e225. doi: 10.1111/jdv.15409. Epub 2019 Feb 28. J Eur Acad Dermatol Venereol. 2019. PMID: 30821007 No abstract available.
• Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.

  Scarisbrick JJ. Scarisbrick JJ. Future Oncol. 2017 Nov;13(27):2405-2411. doi: 10.2217/fon-2017-0263. Epub 2017 Aug 14. Future Oncol. 2017. PMID: 28805086 Review.
• Brentuximab vedotin in CD30⁺ primary cutaneous T-cell lymphomas: a review and analysis of existing data.

  Enos TH, Feigenbaum LS, Wickless HW. Enos TH, et al. Int J Dermatol. 2017 Dec;56(12):1400-1405. doi: 10.1111/ijd.13696. Epub 2017 Aug 1. Int J Dermatol. 2017. PMID: 28762479 Review.